Patients on the trial will get either the antibody or a placebo, along with the antiviral drug remdesivir.
They may also be given dexamethasone - another proven treatment - if the doctor deems it suitable, he said.The monoclonal antibody was developed by American pharmaceutical company Eli Lilly. Phase one trials have shown that it is safe and can improve patients' symptoms and reduce their viral load. Named Activ-3, the trial which started in August has recruited over 200 Covid-19 patients, mainly from the United States and Denmark.
On Tuesday, The Straits Times reported that one of the two antibodies in the cocktail used to treat US President Donald Trump for Covid-19 was developed using blood samples from three patients in Singapore. It is not clear if the current trial being undertaken by the NCID is linked to the earlier development.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: YahooSG - 🏆 3. / 71 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »